ILR-HM2BG-100μg / 询价
ILR-HM2BG-500μg / 询价
ILR-HM2BG-500μgx2 / 询价
Human IL-2 R beta&IL-2 R gamma Protein
Recombinant Human IL-2 R beta&IL-2 R gamma Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Ala27-Thr240 (IL-2 R beta)&Leu23-Ala262 (IL-2 R gamma).[Accession | P14784(IL-2 R beta)&P31785-1(IL-2 R gamma)]
The protein has a predicted MW of 51.3 kDa (IL-2 R beta)&54.6 kDa (IL-2 R gamma). Due to glycosylation, the protein migrates to 65-70 kDa&80-100 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human IL-2 R beta&IL-2 R gamma on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human IL-2 R beta&IL-2 R gamma is greater than 95% as determined by SEC-HPLC.
Immobilized Human IL-15RA&IL-15, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human IL-2 R beta&IL-2 R gamma, hFc Tag with the EC50 of 38.8ng/ml determined by ELISA (QC Test).
Human IL-2 R beta&IL-2 R gamma, hFc Tag captured on CM5 Chip via Protein A can bind Human IL-2, No Tag with an affinity constant of 0.114 nM as determined in SPR assay (Biacore T200).
Human IL-2 R beta&IL-2 R gamma, hFc Tag captured on CM5 Chip via Protein A can bind Human IL-15Ra&IL-15, His Tag with an affinity constant of 0.084 nM as determined in SPR assay (Biacore T200).
Wilms' tumor 1 (WT1) is a transcription factor which plays a major role in cell proliferation, differentiation, survival, and apoptosis. WT1 was first identified as a tumor suppressor gene in Wilms' tumor. The expression of survival signaling genes, IL-2, IL-2RB, and IL-2RG, was also suppressed after WT1-siRNA treatment. In addition, the WT1 silencing also inhibited the S phase of the cell cycle and induced cell death.Moreover, transcriptional modulation of IL-2, IL-2RB, and IL2-2RG expression by WT1 was likely involved in this phenotypic change.
IL-2RB&IL-2RG; IL-2RG; IL-2R subunit gamma; IL-2R subunit beta; IL-2RB; IL15RB; IL-2 R beta&IL-2 R gamma; IL-2R subunit β; IL-2 R β&IL-2 R gamma
(1) Dejjuy D, Dechsukhum C, Pattanapanyasat K, Noulsri E, Dissen GA, Leeanansaksiri W. Novel WT1 Target Genes: IL-2, IL-2RB, and IL-2RG Discovered during WT1 Silencing Using Lentiviral-Based RNAi in Myeloid Leukemia Cells. Biomed Res Int. 2020 Oct 14;2020:7851414. doi: 10.1155/2020/7851414. PMID: 33110919; PMCID: PMC7582064.
